Lupin’s Pegfilgrastim Biosimilar Accepted By US FDA

Neulasta Rival Faces A Crowded Market With Four Approved Competitors

Lupin’s first US biosimilar application, for a rival to Neulasta, has been accepted for filing by the FDA. If approved, the product would join an already crowded market for pegfilgrastim in the US.

Motorbike Race Track Motorcycle
Lupin is planning to join a crowded field for biosimilar pegfilgrastim • Source: Alamy

Lupin has announced that its first 351(k) biologics license application in the US, for its proposed biosimilar version of Neulasta (pegfilgrastim), has been accepted for filing by the US Food and Drug Administration.

CEO Vinita Gupta said the US agency’s acceptance of the BLA for the neutropenia treatment represented “a significant achievement” for...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.